Phathom Pharmaceuticals (PHAT) Financials: Revenue & Earnings
PHAT$6.16+0.17 +2.90%
$498.64M
Market Cap
-4.48
P/E
8.60
Forward P/E
68
Score
Phathom Pharmaceuticals (PHAT) Financials: Revenue & Earnings
PHAT price $6.16 +0.17 +2.90%
- Ticker
- PHAT
- Price
- $6.16
- Change
- +0.17 +2.90%
- Market cap ?
- $498.64M
- P/E ?
- -4.48
- Forward P/E ?
- 8.60
- Dividend yield ?
- 0.00%
- Beta ?
- 0.50
- Sector
- Healthcare
- Industry
- Biotechnology
- Stocklytics score
- 68
- Value
- 60
- Quality
- 44
- Growth
- 100
Stocklytics score rationale: value 60, quality 44, growth 100.
Financials
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| 0 | 0 | 0 | 0 | 0 | 682000 | 55252000 | 175110000 |
Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, Europe, and Canada…
Fair value
PHAT fair value $30.53. Price $6.16. Price is 80% below fair value.
Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price. How discounted cash flow works.
Calculated with a 10-year free-cash-flow discount. Starting free cash flow 52.30M. Growth 20.00%. When analyst earnings forecasts are available, free cash flow in those years is forecast earnings times the company's usual conversion of earnings into free cash flow, kept between 60% and 130%. Years with fewer than 3 analyst estimates are left out. Growth then fades in a straight line to terminal growth by year 10, starting from the last well-covered year's growth, or from the pace across those years when the final year slows sharply, kept between 0% and 20%. Without those forecasts, year-1 growth is analyst revenue growth for the next full fiscal year, or 5-year historical revenue growth when that forecast is missing, held for five years, then fading in a straight line to terminal growth by year 10. Terminal growth 3.00%. Discount rate 8.70% (beta 0.8). Beta is kept between 0.8 and 2.0, which on its own would make the discount rate 8.7% to 15.3%. The rate is then capped at 12%. A cap is used because a discount above 12% pushes higher-beta stocks further from the price. The discount rate stays at least 5 percentage points above terminal growth. Shares 80.90M. Net debt 81.83M. The earnings value is next-12-months earnings per share, or trailing earnings when that forecast is missing, times the stock's own 10-year median P/E, kept between 8 and 40. Fewer than five years of history uses the sector's typical P/E. Fair value is the average of the cash-flow value and the earnings value when both exist. Model uncertainty is high when fair value is more than 60% from the price, or when most of the cash-flow value sits after year 10.
Model uncertainty high for this stock
Earnings
| Date | EPS actual | EPS estimate | Revenue | Revenue estimate |
|---|---|---|---|---|
| 2026-10-29 | — | -0.11 | — | 84.82M |
| 2026-07-30 | -0.21 | -0.18 | 74.27M | 73.23M |
| 2026-04-30 | -0.37 | -0.27 | 58.30M | 55.90M |
| 2026-02-26 | -0.29 | -0.32 | 57.58M | 57.17M |
| 2025-10-30 | -0.41 | -0.40 | 49.50M | 46.99M |
| 2025-08-07 | -0.79 | -0.76 | 39.50M | 46.77M |
| 2025-05-01 | -1.07 | -1.06 | 28.52M | 35.65M |
| 2025-03-06 | -0.79 | -1.29 | 29.66M | 29.04M |
| 2024-11-07 | -1.32 | -1.57 | 16.35M | 25.77M |
| 2024-08-08 | -1.25 | -1.20 | 7.32M | 5.81M |
| 2024-05-09 | -1.42 | -1.43 | 1.91M | 2.05M |
| 2024-03-07 | -1.39 | -1.08 | 682.00K | 400.89K |
| 2023-11-09 | -0.76 | -0.95 | — | 800.00K |
| 2023-08-10 | -0.84 | -0.95 | — | — |
| 2023-05-10 | -0.89 | -1.34 | — | — |
| 2023-02-28 | -1.33 | -1.50 | — | 200.00K |
| 2022-11-08 | -1.32 | -1.32 | — | — |
| 2022-08-02 | -1.33 | -1.03 | — | — |
| 2022-05-10 | -1.07 | -0.97 | — | 211.00K |
| 2022-03-01 | -0.95 | -0.86 | — | — |
| 2021-11-08 | -0.98 | -0.78 | — | — |
| 2021-08-10 | -1.00 | -1.07 | — | — |
| 2021-05-11 | -0.96 | -1.11 | — | — |
| 2021-03-30 | -1.58 | -0.93 | — | — |
| 2020-11-10 | -1.02 | -0.68 | — | — |
| 2020-08-06 | -0.64 | -0.56 | — | — |
| 2020-05-12 | -0.62 | -0.59 | — | — |
| 2020-03-19 | -3.97 | -1.25 | — | — |
| 2019-11-25 | -9.30 | -1.14 | — | — |
| 2019-10-28 | -10.23 | — | — | — |
| 2019-03-31 | -0.15 | — | — | — |
| 2018-12-31 | -0.06 | — | — | — |
| 2018-09-30 | -0.03 | — | — | — |
| 2018-06-30 | -0.05 | — | — | — |
| 2018-03-31 | -0.05 | — | — | — |
Dividends
Yield 0.00%. Payout ratio 0.00%. Frequency —.
Safety score 37/100 · Watch. Payout ratio is 0% of earnings. Free-cash-flow coverage is not available, so this part stays neutral. No dividend history was found. There is no dividend yield.
| Ex-date | Dividend | Record | Payment | Frequency |
|---|---|---|---|---|
| No data yet. | ||||
Insider trades
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-10-06 | Narula Sanjeev | Sell | 13.48K | $6.78 | 91.43K |
| 2026-09-03 | Breedlove Robert Charles | Sell | 460 | $9.05 | 4.16K |
| 2026-07-14 | Breedlove Robert Charles | Sell | 1.55K | $11.04 | 17.16K |
| 2026-05-22 | Parikh Asit | Buy | 28.00K | — | — |
| 2026-05-22 | Parikh Asit | Sell | 28.00K | — | — |
| 2026-05-20 | Parikh Asit | Buy | 17.50K | $4.95 | 86.62K |
| 2026-05-20 | Parikh Asit | Sell | 17.50K | $4.95 | 86.62K |
| 2026-05-19 | Parikh Asit | Buy | 24.12K | — | — |
| 2026-05-19 | Topper James N | Buy | 24.12K | — | — |
| 2026-05-19 | Stenhouse Mark | Buy | 24.12K | — | — |
| 2026-05-19 | FIELDS HEIDI | Buy | 24.12K | — | — |
| 2026-05-19 | COLA MICHAEL F | Buy | 24.12K | — | — |
| 2026-05-19 | KARBE FRANK | Buy | 24.12K | — | — |
| 2026-05-19 | Schroeder Theodore R | Buy | 24.12K | — | — |
| 2026-03-10 | Parikh Asit | Buy | 40.00K | — | — |
| 2026-03-10 | Parikh Asit | Sell | 40.00K | — | — |
| 2026-02-27 | Breedlove Robert Charles | Buy | 2.79K | — | — |
| 2026-02-27 | Breedlove Robert Charles | Sell | 964 | $12.56 | 12.11K |
| 2026-02-27 | Breedlove Robert Charles | Sell | 414 | $12.56 | 5.20K |
| 2026-02-27 | Breedlove Robert Charles | Buy | 13.00K | — | — |
| 2026-02-10 | Cook Anne Marie | Buy | 3.46K | — | — |
| 2026-02-10 | Cook Anne Marie | Sell | 1.53K | $12.82 | 19.68K |
| 2026-02-10 | Basta Steven L | Buy | 12.36K | — | — |
| 2026-02-10 | Basta Steven L | Sell | 6.28K | $12.82 | 80.47K |
| 2026-01-23 | Parikh Asit | Buy | 80.50K | — | — |
| 2026-01-23 | Parikh Asit | Sell | 80.50K | — | — |
| 2026-01-21 | Breedlove Robert Charles | Sell | 776 | $13.61 | 10.56K |
| 2026-01-13 | Parikh Asit | Buy | 8.75K | $10.30 | 90.12K |
| 2026-01-13 | Parikh Asit | Sell | 8.75K | $10.30 | 90.12K |
| 2026-01-02 | Basta Steven L | Buy | 251.03K | — | — |
| 2026-01-02 | Basta Steven L | Buy | 226.16K | $15.71 | 3.55M |
| 2026-01-02 | Cook Anne Marie | Buy | 75.34K | — | — |
| 2026-01-02 | Cook Anne Marie | Buy | 67.88K | $15.71 | 1.07M |
| 2026-01-02 | Narula Sanjeev | Buy | 82.72K | — | — |
| 2026-01-02 | Narula Sanjeev | Buy | 42.85K | $15.71 | 673.14K |
| 2025-12-19 | Parikh Asit | Buy | 8.75K | $10.30 | 90.12K |
| 2025-12-19 | Parikh Asit | Sell | 8.75K | $10.30 | 90.12K |
| 2025-12-18 | Breedlove Robert Charles | Sell | 230 | $16.28 | 3.74K |
| 2025-12-17 | Cook Anne Marie | Buy | 17.37K | — | — |
| 2025-12-17 | Cook Anne Marie | Sell | 7.70K | $15.36 | 118.32K |
| 2025-12-17 | Basta Steven L | Buy | 62.04K | — | — |
| 2025-12-17 | Basta Steven L | Sell | 31.50K | $15.36 | 483.87K |
| 2025-11-28 | Basta Steven L | Sell | 90.00K | — | — |
| 2025-11-28 | Basta Steven L | Buy | 90.00K | — | — |
| 2025-11-28 | Basta Steven L | Sell | 48.38K | $15.62 | 755.62K |
| 2025-11-03 | Breedlove Robert Charles | Sell | 524 | $13.51 | 7.08K |
| 2025-10-06 | Narula Sanjeev | Buy | 144.00K | — | — |
| 2025-10-06 | Narula Sanjeev | Buy | 200.00K | $11.61 | 2.32M |
| 2025-10-06 | Narula Sanjeev | Other | 0 | — | — |
| 2025-09-25 | Basta Steven L | Sell | 90.00K | — | — |
| 2025-09-25 | Basta Steven L | Buy | 90.00K | — | — |
| 2025-09-25 | Basta Steven L | Sell | 48.38K | $11.66 | 564.05K |
| 2025-09-05 | Breedlove Robert Charles | Sell | 461 | $12.09 | 5.57K |
| 2025-07-16 | Breedlove Robert Charles | Sell | 1.69K | $8.36 | 14.15K |
| 2025-06-23 | Cook Anne Marie | Buy | 210.00K | $9.47 | 1.99M |
| 2025-06-23 | Cook Anne Marie | Other | 0 | — | — |
| 2025-06-03 | KARBE FRANK | Buy | 10.50K | — | — |
| 2025-06-03 | KARBE FRANK | Buy | 17.50K | $4.95 | 86.62K |
| 2025-06-03 | COLA MICHAEL F | Buy | 10.50K | — | — |
| 2025-06-03 | COLA MICHAEL F | Buy | 17.50K | $4.95 | 86.62K |
| 2025-06-03 | Topper James N | Buy | 10.50K | — | — |
| 2025-06-03 | Topper James N | Buy | 17.50K | $4.95 | 86.62K |
| 2025-06-03 | FIELDS HEIDI | Buy | 10.50K | — | — |
| 2025-06-03 | FIELDS HEIDI | Buy | 17.50K | $4.95 | 86.62K |
| 2025-06-03 | Stenhouse Mark | Buy | 10.50K | — | — |
| 2025-06-03 | Stenhouse Mark | Buy | 17.50K | $4.95 | 86.62K |
| 2025-06-03 | Parikh Asit | Buy | 10.50K | — | — |
| 2025-06-03 | Parikh Asit | Buy | 17.50K | $4.95 | 86.62K |
| 2025-05-21 | Topper James N | Buy | 3.78K | $3.86 | 14.61K |
| 2025-05-19 | Breedlove Robert Charles | Buy | 33.00K | $4.39 | 144.87K |
| 2025-05-14 | Topper James N | Buy | 6.30K | $3.32 | 20.92K |
| 2025-05-13 | Topper James N | Buy | 1.12K | $3.16 | 3.54K |
| 2025-05-12 | Topper James N | Buy | 12.60K | $3.04 | 38.30K |
| 2025-05-09 | Topper James N | Buy | 2.23K | $3.62 | 8.05K |
| 2025-05-09 | Topper James N | Buy | 33.38K | $3.19 | 106.56K |
| 2025-05-07 | Parikh Asit | Buy | 5.00K | $2.40 | 11.98K |
| 2025-05-06 | Parikh Asit | Buy | 5.00K | $2.60 | 13.00K |
| 2025-05-01 | Breedlove Robert Charles | Other | 0 | — | — |
| 2025-05-01 | Breedlove Robert Charles | Other | 0 | — | — |
| 2025-05-01 | Breedlove Robert Charles | Other | 13.50K | $8.35 | 112.72K |
| 2025-05-01 | Breedlove Robert Charles | Other | 12.00K | $15.21 | 182.52K |
| 2025-05-01 | Breedlove Robert Charles | Other | 15.75K | $7.60 | 119.70K |
| 2025-05-01 | Breedlove Robert Charles | Other | 15.00K | $5.76 | 86.40K |
| 2025-04-16 | Schroeder Theodore R | Buy | 35.00K | $4.23 | 148.05K |
| 2025-04-16 | Schroeder Theodore R | Buy | 21.00K | — | — |
| 2025-04-16 | Schroeder Theodore R | Other | 0 | — | — |
| 2025-04-07 | Henderson Molly | Sell | 3.68K | $4.55 | 16.74K |
| 2025-04-03 | Basta Steven L | Buy | 1.08M | $5.01 | 5.44M |
| 2025-04-03 | Basta Steven L | Buy | 360.00K | — | — |
| 2025-04-01 | Basta Steven L | Other | 0 | — | — |
| 2025-03-13 | Parikh Asit | Buy | 10.00K | $4.42 | 44.20K |
| 2025-02-27 | Curran Terrie | Buy | 342.50K | $5.76 | 1.97M |
| 2025-02-27 | Henderson Molly | Buy | 72.00K | — | — |
| 2025-02-27 | Henderson Molly | Buy | 50.00K | $5.76 | 288.00K |
| 2025-02-27 | Nabulsi Azmi | Buy | 79.20K | — | — |
| 2025-02-27 | Nabulsi Azmi | Buy | 55.00K | $5.76 | 316.80K |
| 2025-01-21 | Henderson Molly | Sell | 6.58K | $6.59 | 43.37K |
| 2025-01-21 | Nabulsi Azmi | Sell | 7.89K | $6.59 | 51.96K |
| 2025-01-21 | Curran Terrie | Sell | 19.11K | $6.59 | 125.88K |
| 2024-12-19 | Nabulsi Azmi | Sell | 1.12K | $8.00 | 8.94K |
Institutional holders
Latest filed quarter: Q2 2026.
Institutions holding: 173, holders -6 vs prior quarter. Ownership 86.56%.
| Holder | Shares | Change | Change % | Value |
|---|---|---|---|---|
| FRAZIER LIFE SCIENCES MANAGEMENT, L.P. | 12.47M | 0 | 0.00% | 135.26M |
| MEDICXI VENTURES MANAGEMENT (JERSEY) LTD | 7.46M | 0 | 0.00% | 80.99M |
| BLACKROCK, INC. | 4.53M | 463.13K | +11.40% | 49.10M |
| INVESCO LTD. | 4.03M | -292.33K | -6.76% | 43.72M |
| CARLYLE GROUP INC. | 3.50M | 0 | 0.00% | 37.94M |
| MILLENNIUM MANAGEMENT LLC | 3.38M | -647.08K | -16.08% | 36.63M |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.66M | 73.31K | +2.84% | 28.83M |
| GW&K INVESTMENT MANAGEMENT, LLC | 2.17M | 745.73K | +52.48% | 23.51M |
| FRANKLIN TEMPLETON INC | 1.97M | 976.32K | +98.17% | 21.38M |
| NEA MANAGEMENT COMPANY, LLC | 1.96M | 0 | 0.00% | 21.27M |
| 683 CAPITAL MANAGEMENT, LLC | 1.85M | 0 | 0.00% | 20.07M |
| GOLDMAN SACHS GROUP INC | 1.78M | 1.15M | +183.94% | 19.29M |
| STATE STREET CORP | 1.59M | 199.43K | +14.38% | 17.21M |
| CATALYS PACIFIC, LLC | 1.49M | 0 | 0.00% | 16.21M |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 1.46M | 257.37K | +21.35% | 15.87M |
| GEODE CAPITAL MANAGEMENT, LLC | 1.32M | -12.36K | -0.93% | 14.28M |
| WASATCH ADVISORS LP | 1.31M | -33.67K | -2.51% | 14.18M |
| ENSIGN PEAK ADVISORS, INC | 1.05M | -575.89K | -35.38% | 11.41M |
| PROPEL BIO MANAGEMENT, LLC | 1.05M | 209.09K | +24.85% | 11.40M |
| POINT72 ASSET MANAGEMENT, L.P. | 1.02M | 1.02M | New | 11.09M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 796.63K | 130.60K | +19.61% | 8.64M |
| SUMMITTX CAPITAL, L.P. | 789.55K | -206.34K | -20.72% | 8.57M |
| HSBC HOLDINGS PLC | 709.70K | 709.70K | New | 7.70M |
| MARSHALL WACE, LLP | 666.09K | -194.60K | -22.61% | 7.23M |
| ECOR1 CAPITAL, LLC | 625.00K | 0 | 0.00% | 6.78M |
Earnings and financials
Phathom Pharmaceuticals, Inc. (PHAT) trades at $6.16, with a market cap of $498.64M and a trailing P/E of -4.48. Revenue below is the annual history on file. It describes what the business has already reported. It is not a forecast and it is not a recommendation.
Financials
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| 0 | 0 | 0 | 0 | 0 | 682000 | 55252000 | 175110000 |
Insights · Dividends · Forecast · Financials · Learn